<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691974</url>
  </required_header>
  <id_info>
    <org_study_id>R475-OA-1758</org_study_id>
    <secondary_id>2017-004921-33</secondary_id>
    <nct_id>NCT03691974</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceutical Industries, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the effect of fasinumab compared to placebo
      on peripheral nerves in participants with pain due to Osteoarthritis (OA) of the hip or knee.

      The secondary objectives of the study are to:

        -  Evaluate the efficacy of fasinumab compared to placebo in participants with pain due to
           OA of the hip or knee

        -  Evaluate the safety and tolerability of fasinumab compared to placebo in participants
           with pain due to OA of the hip or knee

        -  Characterize the concentrations of fasinumab in serum in participants with pain due to
           OA of the hip or knee

        -  Evaluate the immunogenicity of fasinumab in participants with pain due to OA of the hip
           or knee.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Anticipated">December 18, 2020</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in peroneal motor nerve conduction velocity</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>An electrophysiological evaluation using standard electrophysiological techniques to measure the speed and extent of nerve conduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in peroneal motor nerve action potential amplitude</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>An electrophysiological evaluation using standard electrophysiological techniques to measure the speed and extent of nerve conduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sural sensory nerve conduction velocity</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>An electrophysiological evaluation using standard electrophysiological techniques to measure the speed and extent of nerve conduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sural sensory nerve action potential amplitude</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>An electrophysiological evaluation using standard electrophysiological techniques to measure the speed and extent of nerve conduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ulnar sensory nerve conduction velocity</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>An electrophysiological evaluation using standard electrophysiological techniques to measure the speed and extent of nerve conduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ulnar sensory nerve action potential amplitude</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>An electrophysiological evaluation using standard electrophysiological techniques to measure the speed and extent of nerve conduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC physical function subscale score</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated arthropathy (AA)</measure>
    <time_frame>Week 16</time_frame>
    <description>As confirmed by an independent adjudication committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated arthropathy (AA)</measure>
    <time_frame>Week 36</time_frame>
    <description>As confirmed by an independent adjudication committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Destructive arthropathy (DA)</measure>
    <time_frame>Week 16</time_frame>
    <description>As confirmed by an independent adjudication committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Destructive arthropathy (DA)</measure>
    <time_frame>Week 36</time_frame>
    <description>As confirmed by an independent adjudication committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse event (TEAEs)</measure>
    <time_frame>Up to 64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Sympathetic Nervous System (SNS) dysfunction</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>As diagnosed after consultation with an appropriate specialist, such as a neurologist and/or cardiologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of peripheral sensory Adverse Events (AEs) that require a neurology consultation</measure>
    <time_frame>Up to 64 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause joint replacement (JR) surgeries</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause JR surgeries</measure>
    <time_frame>Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of JRs at telephone survey</measure>
    <time_frame>52 weeks after last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Osteoarthritis, Hip</condition>
  <arm_group>
    <arm_group_label>Fasinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fasinumab</intervention_name>
    <description>Subcutaneous (SC) every four weeks (Q4W)</description>
    <arm_group_label>Fasinumab</arm_group_label>
    <other_name>REGN475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous (SC) every four weeks (Q4W)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. A clinical diagnosis of OA of the knee or hip based on the American College of
             Rheumatology criteria with radiologic evidence of OA (K-L score ≥2 for the index
             joint) at the screening visit

          2. Moderate-to-severe pain in the index joint defined as a WOMAC average pain subscale
             score of ≥4 at both the screening and randomization visits

          3. Willing to discontinue current pain medications and to adhere to study requirements
             for rescue treatments

          4. A history of regular use of analgesic medications for OA pain (defined as an average
             of 4 days per week over the 4 weeks prior to the screening visit), including oral
             nonsteroidal anti-inflammatory drugs (NSAIDs), selective cyclooxygenase 2 inhibitors,
             opioids, paracetamol/acetaminophen, or combinations thereof

          5. Consent to allow all radiographs and medical/surgical/hospitalization records of care
             received elsewhere prior to and during the study period to be shared with the
             investigator

        Key Exclusion Criteria:

          1. History or presence at the screening visit of non-OA inflammatory joint disease (eg,
             rheumatoid arthritis, lupus erythematosus, psoriatic arthritis, pseudo-gout, gout,
             spondyloarthropathy, polymyalgia rheumatica, joint infections within the past 5
             years), Paget's disease of the spine, pelvis or femur, neuropathic disorders, multiple
             sclerosis, fibromyalgia, tumors or infections of the spinal cord, or renal
             osteodystrophy

          2. History or presence on imaging of arthropathy (osteonecrosis, subchondral
             insufficiency fracture, rapidly progressive OA type 1 or type 2), stress fracture,
             recent stress fracture, neuropathic joint arthropathy, hip dislocation (prosthetic hip
             dislocation is eligible), knee dislocation (patella dislocation is eligible),
             congenital hip dysplasia with degenerative joint disease, extensive subchondral cysts,
             evidence of bone fragmentation or collapse, or primary metastatic tumor with the
             exception of chondromas or pathologic fractures during the screening period

          3. Trauma to the index joint within 3 months prior to the screening visit

          4. History or presence of signs or symptoms of compression neuropathy, including carpal
             tunnel syndrome or sciatica

          5. Participant is not a candidate for Magnetic Resonance Imaging (MRI)

          6. Poorly controlled diabetes

          7. Known history of human immunodeficiency virus (HIV) infection

          8. Known history of ocular herpes simplex virus, herpes simplex virus pneumonia, or
             herpes simplex virus encephalitis

          9. History of poorly controlled hypertension

         10. Known history of infection with hepatitis B or C virus

        Note: Other protocol defined Inclusion/Exclusion apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Caro</city>
        <state>Michigan</state>
        <zip>48723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Hartsdale</city>
        <state>New York</state>
        <zip>10530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>72858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>91-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-382</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-537</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Czestochowa</city>
        <state>Slaskie</state>
        <zip>42-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-702</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-127</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>WC1X8QD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chorley</city>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Corby</city>
        <zip>NN172UR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Edgbaston</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Hardwick</city>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Hexham</city>
        <zip>NE46 1QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Kenilworth</city>
        <zip>CV81JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regulatory Study Site</name>
      <address>
        <city>London</city>
        <zip>DA146LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>London</city>
        <zip>RG401XS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>London</city>
        <zip>RM13PJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Northwood</city>
        <zip>HA62RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Peterborough</city>
        <zip>PE73JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Reading</city>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Shipley</city>
        <zip>BD183SL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Waterloo</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasinumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

